Share on StockTwits

Cubist Pharmaceuticals (NASDAQ:CBST) EVP Steven C. Gilman sold 16,340 shares of Cubist Pharmaceuticals stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $67.82, for a total transaction of $1,108,178.80. Following the completion of the sale, the executive vice president now directly owns 27,598 shares of the company’s stock, valued at approximately $1,871,696. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

CBST has been the subject of a number of recent research reports. Analysts at Ned Davis Research upgraded shares of Cubist Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note on Friday, April 25th. They now have a $70.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Cubist Pharmaceuticals from $80.00 to $90.00 in a research note on Monday, April 21st. They now have an “outperform” rating on the stock. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $75.07.

Shares of Cubist Pharmaceuticals (NASDAQ:CBST) traded down 4.21% on Thursday, hitting $66.41. 950,887 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 1-year low of $47.14 and a 1-year high of $82.12. The stock’s 50-day moving average is $68.30 and its 200-day moving average is $69.84. The company’s market cap is $5.001 billion.

Cubist Pharmaceuticals (NASDAQ:CBST) last announced its earnings results on Tuesday, April 22nd. The company reported $0.30 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.33 by $0.03. The company had revenue of $261.20 million for the quarter, compared to the consensus estimate of $285.24 million. During the same quarter last year, the company posted $0.34 earnings per share. Cubist Pharmaceuticals’s revenue was up 13.6% compared to the same quarter last year. On average, analysts predict that Cubist Pharmaceuticals will post $0.50 earnings per share for the current fiscal year.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.